Karyopharm Therapeutics (KPTI) Treasury Shares (2012 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Treasury Shares came in at $1.3 million in Q4 2025, up 55.59% YoY from $850738.0 in Q4 2024, and up 55.59% on a QoQ basis from $850738.0 in Q4 2024.
Karyopharm Therapeutics (KPTI) Treasury Shares (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Treasury Shares data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Treasury Shares rose 55.59% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 55.59% YoY) and the FY2025 annual result came in at $1.3 million, up 55.59% from the prior year.
- Treasury Shares advanced to $1.3 million in Q4 2025, from $850738.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $7.7 million in Q4 2023 to a low of $850738.0 in Q4 2024.
- A 5-year average of $3.1 million and a median of $2.3 million in 2021 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares surged 125.3% — and 2024, when it sank 88.9%.
- Tracing KPTI's Treasury Shares over 5 years: stood at $2.3 million in 2021, then surged by 47.91% to $3.4 million in 2022, then soared by 125.3% to $7.7 million in 2023, then slumped by 88.9% to $850738.0 in 2024, then soared by 55.59% to $1.3 million in 2025.
- The last three Treasury Shares figures came in at $1.3 million (Q4 2025), $850738.0 (Q4 2024), and $7.7 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 850,738.00 |
| Dec 31, 2024 | 850,738.00 |
| Dec 31, 2023 | 7.67 Mn |
| Dec 31, 2023 | 7.67 Mn |
| Dec 31, 2022 | 3.40 Mn |
| Dec 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Dec 31, 2020 | 1.67 Mn |
| Dec 31, 2020 | 1.67 Mn |
| Mar 31, 2018 | 203.10 Mn |
| Mar 31, 2018 | 203.10 Mn |
| Dec 31, 2017 | 253,100.00 |
| Dec 31, 2017 | 253,100.00 |
| Sep 30, 2017 | 425,850.00 |
| Sep 30, 2017 | 425,850.00 |
| Jun 30, 2017 | 439,250.00 |
| Jun 30, 2017 | 439,250.00 |